melanocortin agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-16. Numbers and descriptions here follow the published literature rather than marketing material.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
== Function == M-protein exhibits a different pattern of expression in cardiac and skeletal muscle, as well as fast- versus slow-skeletal muscle during development, suggesting different regulatory mechanisms for expression quantity and temporal appearance. In cardiac muscle, expression of M-protein continues to increase from neonatal to adult; however, in skeletal muscle, M-protein mRNA expression is biophasic. M-protein is initially present in both slow- and fast-skeletal muscle embryonic fibers, then M-protein is suppressed in slow fibers. The embryonic splice variant of myomesin, termed EH-myomesin, is expressed in a complementary pattern with M-protein during development in higher vertebrates. It was also shown that the mRNA expression of M-protein is exquisitely sensitive to thyroid hormone (T3); M-protein expression, but not MYOM1 or its variant, EH-myomesin, was rapidly reduced by T3 in vivo and in vitro. The M-protein promoter is responsive to T3, and was suggested to contain thyroid hormone response elements near the transcriptional start point. The giant protein titin, together with its associated proteins, interconnects the major structure of sarcomeres, the M bands and Z discs. The C-terminal end of the titin string extends into the M line, where it binds tightly to M-band constituents MYOM1 and M-protein, of apparent molecular masses of 190 kD and 165 kD, respectively.
Joy Stevenson Heeley, lately Revenue Officer, Board of Inland Revenue. Thomas William Heler, Member, Staffordshire Parish Councils Association. For services to Local Government. Mabel Evelyn Jeanette Henderson. For services to the Guide Association in Shetland. Joan Elizabeth Hetherington. For public service. Major John Wilfred Barratt Hext, , Voluntary Observer, Meteorological Office, Cumbria. Sheila Jean Hibbert. For services to Young People in London. Herbert Vincent Higgins. For services to the Retired and Senior Volunteer Programme. Eileen Jeanne Hodder. For services to the community in Richmond upon Thames, Surrey. Eileen Hodgkinson. For political and public service Marjone Hodgson. For services to the community in York. Mavis Ruth Hogg. For services to Lawn Tennis. Olive Holden. For services to the Cancer Relief Macmillan Fund in Perthshire. David George Holland, Senior Road Safety Officer, Durham County Council. For services to Road Safety. John Kenneth Hollis. For charitable services in Kent. Thomas Holmes, lately Assistant Director, Environmental Services, Trafford Metropolitan Borough Council. For services to the Environment. Albert Joseph Thomas Honey. For services to Animal Welfare in Oxfordshire. James William Hopkins, lately Manager, District Office, East Midlands Electricity plc. For services to the Electricity Industry. Robert Hopper, Road Worker, Highways Division, Northumberland Contracting. For services to Highways Maintenance. Olive Mary Hopton. For services to the community in Irlam, Manchester. Beve Hornsby. For services to People with Dyslexia.
=== Kalaghatgi === Following the 2008 delimitation of Karnataka's constituencies, Lad contested the Kalaghatgi Assembly constituency on a Congress ticket. He defeated BJP candidate C. M. Nimbannavar by 11,642 votes, receiving 49,733 votes. In the 2013 Karnataka Legislative Assembly election, Lad was re-elected from Kalaghatgi. He received 76,802 votes, defeating his nearest rival by more than 45,000 votes. In 2018, Lad contested Kalaghatgi again but was defeated by BJP candidate C. M. Nimbannavar. Nimbannavar received 83,267 votes compared with Lad's 57,270, a margin of 25,997 votes. Lad returned to the Assembly in the 2023 Karnataka election. He won Kalaghatgi with 85,761 votes, defeating BJP candidate Nagaraj Chebbi, who received 71,404 votes. The margin was 14,357 votes.
Wool Bradford, Halifax and Huddersfield grew through the development of woollen mills. Leeds' traditional industry was the manufacturing of cloth while heavier engineering industries facilitated growth in South Leeds. The Heavy Woollen District covered towns such as Dewsbury, Batley, Morley, Ossett, Cleckheaton and Heckmondwike. The woollen and cloth industries declined throughout the twentieth century.
Sources: en.wikipedia.org
Amis, Moses N. (1913). Historical Raleigh. With Sketches of Wake County (from 1771) and Its Important Towns; Descriptive, Biographical, Educational, Industrial, Religious (Enlarged and Revised ed.). Raleigh: Commercial Printing Co. Benjamin, Karen (March 2012). "Suburbanizing Jim Crow: The Impact of School Policy on Residential Segregation in Raleigh". Journal of Urban History, 38(2), pp. 225–46. doi:10.1177/0096144211427114. By-Laws of Harry Burgwyn Camp, Number 166, United Sons of Confederate Veterans, Raleigh, N. C. (Report). Camp Publication, No. 1. Raleigh: Alford, Bynum & Christophers, Job Printers. 1900. Charter Members of Harry Burgwyn Camp, Number 166, United Sons of Confederate Veterans, Raleigh, N. C.: Including Records of Ancestors through Whom they derive Eligibility (Report). Camp Publication, No. 2. Raleigh: Alford, Bynum & Christophers, Job Printers. 1900.
==== MeSH D06.472.334 – gonadal hormones ==== MeSH D06.472.334.500 – activins MeSH D06.472.334.500.500 – inhibin-beta subunits MeSH D06.472.334.734 – corpus luteum hormones MeSH D06.472.334.734.623 – progesterone MeSH D06.472.334.734.769 – relaxin MeSH D06.472.334.851 – gonadal steroid hormones MeSH D06.472.334.851.437 – estradiol congeners MeSH D06.472.334.851.437.249 – equilenin MeSH D06.472.334.851.437.374 – equilin MeSH D06.472.334.851.437.500 – estradiol MeSH D06.472.334.851.437.750 – estriol MeSH D06.472.334.851.437.750.320 – estetrol MeSH D06.472.334.851.437.968 – estrogenic steroids, alkylated MeSH D06.472.334.851.437.968.500 – ethinyl estradiol MeSH D06.472.334.851.437.968.500.250 – ethinyl estradiol-norgestrel combination MeSH D06.472.334.851.437.968.500.500 – mestranol MeSH D06.472.334.851.437.968.500.750 – quinestrol MeSH D06.472.334.851.437.984 – estrogens, catechol MeSH D06.472.334.851.437.984.350 – hydroxyestrones MeSH D06.472.334.851.437.988 – estrogens, conjugated (usp) MeSH D06.472.334.851.437.994 – estrogens, esterified (usp) MeSH D06.472.334.851.437.996 – estrone MeSH D06.472.334.851.687 – progesterone congeners MeSH D06.472.334.851.687.500 – pregnenolone MeSH D06.472.334.851.687.500.500 – 17-alpha-hydroxypregnenolone MeSH D06.472.334.851.687.750 – progesterone MeSH D06.472.334.851.687.750.074 – 20-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.099 – 5-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.478 – hydroxyprogesterones MeSH D06.472.334.851.687.750.478.400 – 17-alpha-hydroxyprogesterone MeSH D06.472.334.851.687.750.478.400.500 – pregnanetriol MeSH D06.472.334.851.687.750.739 – pregnanediol MeSH D06.472.334.851.968 – testosterone congeners MeSH D06.472.334.851.968.500 – androstane-3,17-diol MeSH D06.472.334.851.968.750 – androstenediol MeSH D06.472.334.851.968.875 – androstenedione MeSH D06.472.334.851.968.937 – androsterone MeSH D06.472.334.851.968.952 – dehydroepiandrosterone MeSH D06.472.334.851.968.952.300 – dehydroepiandrosterone sulfate MeSH D06.472.334.851.968.964 – dihydrotestosterone MeSH D06.472.334.851.968.968 – etiocholanolone MeSH D06.472.334.851.968.976 – nandrolone MeSH D06.472.334.851.968.984 – testosterone MeSH D06.472.334.851.968.984.500 – epitestosterone MeSH D06.472.334.851.968.984.750 – testosterone propionate MeSH D06.472.334.968 – inhibins MeSH D06.472.334.968.500 – inhibin-beta subunits MeSH D06.472.334.984 – testicular hormones
Although orphan disease populations are the smallest, the cost of per-patient outlays among them are the largest and are expected to increase as more people with rare diseases become eligible for subsidies – in the U.S., for example, through the Affordable Care Act.
=== Stored-waveform inverse Fourier transform === Stored-waveform inverse Fourier transform (SWIFT) is a method for the creation of excitation waveforms for FTMS. The time-domain excitation waveform is formed from the inverse Fourier transform of the appropriate frequency-domain excitation spectrum, which is chosen to excite the resonance frequencies of selected ions. The SWIFT procedure can be used to select ions for tandem mass spectrometry experiments.
== History == The company was founded in 1929 by Dharampal Sugandhi in Chandni Chowk, Delhi, as a perfumery business producing incense sticks, rose water, and tobacco products. In 1958, Satyapal Sugandhi introduced the BABA tobacco brand. During the 1980s, the group diversified into packaged foods with the launch of Catch Salt & Pepper (1987), followed by Catch Natural Spring Water in 1999. The group's subsequent launches included confectionery products under brands such as Rajnigandha, Pass Pass, and Pulse Candy. In 2019, the DS Group acquired an 11–18% stake in the Switzerland-based Lalique Group . In 2023, it introduced the Swiss chocolate brand Läderach to India and acquired the Indian confectionery brand LuvIt.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.